Experts urge caution over drug company campaigns to destigmatize obesity

Experts in The BMJ warn that pharmaceutical campaigns to destigmatize obesity can be both scientifically valid and commercially strategic, using Eli Lilly’s U.K. “Obesity Is a Disease” campaign as a key example. The core concern is that compassion-based messaging may shift obesity policy toward drug-centered clinical treatment and away from broader social and environmental causes.